arrow
D

David Gentien

Institut Curie
H指数:42
被引数:7,141

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular and cellular composition changes after neoadjuvant letrozole and palbociclib in early luminal breast cancer

新辅助来曲唑和帕博西利布治疗早期腔型乳腺癌后的分子和细胞组成变化

2026-01-090
OAAI
NANOPORE SEQUENCING AS A CUTTING-EDGE TECHNOLOGY FOR MEDULLOBLASTOMA CLASSIFICATION
2024-06-180
OAAI
Multi-omics comparison of malignant and normal uveal melanocytes reveals molecular features of uveal melanoma
2023-09-015
OAAI
Evidence of inter- and intra-keloid heterogeneity through analysis of dermal fibroblasts: A new insight in deciphering keloid physiopathology

通过分析真皮成纤维细胞证明瘢痕疙瘩间和内部异质性: 解读瘢痕疙瘩病理生理学的新见解

2023-05-065
PRE
HORMAD1 overexpression predicts response to anthracycline-cyclophosphamide and survival in triple-negative breast cancers
2023-03-236
OA
Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks
2023-03-226
OAAI
Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology

人工智能直接从肝细胞癌组织学中预测免疫和炎症基因特征

2022-07-0154
OAAI
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer

来曲唑和帕博西尼新辅助化疗与第三代化疗对高危雌激素受体阳性HER2-negative乳腺癌患者的生存结果

2022-05-0119
OAAI
A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression
2021-09-2258
OAAI
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial
2021-06-2318
OAAI
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance
2020-08-1391
OAAI